 EMERYVILLE, Calif., June 17, 2021 GLOBE NEWSWIRE -- Gritstone bio, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the Compensation Committee of the companys Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 24,950 shares of its common stock, as an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635c4. 